Cargando…
No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma
Autores principales: | Safi, Mohammed, Trapani, Dario, Alradhi, Mohammed, Shan, Xiu, Jiwei, Liu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262132/ https://www.ncbi.nlm.nih.gov/pubmed/34257604 http://dx.doi.org/10.3389/pore.2021.639004 |
Ejemplares similares
-
Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016
por: Bogos, Krisztina, et al.
Publicado: (2021) -
Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2020) -
Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies
por: Szász, Róbert, et al.
Publicado: (2021) -
Increasing Embryonic Morphogen Nodal Expression Suggests Malignant Transformation in Colorectal Lesions and as a Potential Marker for CMS4 Subtype of Colorectal Cancer
por: Wang, Xiaopai, et al.
Publicado: (2021) -
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells
por: Cruz-Rico, Graciela, et al.
Publicado: (2021)